The cancer pathways, proteoglycans in the tumor microenvironment, EGFR tyrosine kinase pathway, and PI3K-Akt signaling pathway may correlate with the therapeutic effect of TSAC in treating breast cancer. This evidence concerns the gene AKT1 and neoplasm.